Recently, small molecule photoacoustic sensors have emerged prominently in chem/biosensing owing to their excellent performance of high contrast, high resolution, and deep penetration depth. However, there has been little report on a photoacoustic sensor for Pd 2+ detection so far. Herein, a ratiometric photoacoustic Pd 2+ sensor, Cy-DPA, based on cyanine fluorophore has been developed. The absorbance peak of Cy-DPA shifts from 710 to 770 nm after the interaction with Pd 2+ , thus producing a strong PA signal output at 770 nm. As-prepared Cy-DPA could sensing palladium with high sensitivity (27 nM) and selectivity in a fast response (<30 s), which opened new avenue for Pd 2+ real-time detection in vivo.P alladium, is mostly inert in the body as a bulk metal.However, there are reports of contact dermatitis when palladium is used in jewelry or dentistry. In addition, palladium is being widely used as a catalyst in organic coupling reactions, for instance, the Heck reaction, 1,2 Stille coupling, 3 the Suzuki reaction, 4,5 Buchwald-Hartwig coupling, 6 and so on. 7 These reactions play an indispensable role in organic synthesis, including medicinal synthesis (such as Gefitinib, Imatinib, and Tebipenem Pivoxil). 8−10 Even after many times of the purification process, there are is still some palladium residue in these medicines. 11,12 Unfortunately, the palladium residue can strongly stimulate the skin and eyes of human and interact with biological macromolecules such as sulfur-containing amino acids, DNA, RNA, protein, and vitamin B 6 after entering into the human body due to their strong complexation. 4,10,13−16 The palladium residue will disturb many normal functions of cells, which will lead to asthma, alopecia, and even abortion. The European Agency for the Evaluation of Medicinal Products has clearly stipulated the threshold of palladium in drugs is 5−10 ppm, and the limit of dietary intake is less than 1.5−15 μg per person per day. 17,18 Therefore, it is necessary to construct an efficient, highly selective, sensitive, and short-time response sensor for detection of palladium.Traditional analytical methods 19 for Pd 2+ detection are generally based on atomic absorption spectrometry (AAS), inductively coupled plasma (ICP), solid phase microextractionhigh-performance liquid chromatography (SPME-HPLC) and X-ray fluorescence (XRF), but these techniques usually require precision instruments, complex sample pretreatment procedures, and strict experimental conditions, making it difficult for real-time monitoring Pd 2+ in living systems. 20,21 Excellent optical sensors for the detection of Pd 2+ seemed to be an ideal

No abstract

Cancer is one of the leading causes of death across the world, and the prevalence and mortality rates of cancer will continue to grow. Chemotherapeutics play a critical role in cancer therapy, but drug resistance and side effects are major hurdles to effective treatment, evoking an immediate need for the discovery of new anticancer agents. Triazines including 1,2,3-, 1,2,4-, and 1,3,5-triazine have occupied a propitious place in drug design and development due to their excellent pharmacological profiles. Mechanistically, triazine derivatives could interfere with various signaling pathways to induce cancer cell death. Hence, triazine derivatives possess potential in vitro and in vivo efficacy against diverse cancers. In particular, triazine hybrids are able to overcome drug resistance and reduce side effects.Moreover, several triazine hybrids such as brivanib (indole-containing pyrrolo[2,1-f ][1,2,4]triazine), gedatolisib (1,3,5-triazine-urea hybrid), and enasidenib (1,3, 5-triazine-pyridine hybrid) have already been available in the market. Accordingly, triazine hybrids are useful scaffolds for the discovery of novel anticancer chemotherapeutics. This review focuses on the anticancer activity of 1,2,3-, 1,2, 4-, and 1,3,5-triazine hybrids, together with the structure-activity relationships and mechanisms of action developed from 2017 to the present. The enriched structure-activity relationships may be useful for further rational drug development of triazine hybrids as potential clinical candidates.